Project desription
Statins are widely prescribed for managing dyslipidaemia and preventing cardiovascular disease (CVD). However, concerns have arisen regarding their potential to increase the risk of type 2 diabetes. While randomised controlled trials suggest a 10–20% increased diabetes risk, observational studies indicate an even stronger association. The underlying mechanisms remain unclear but are believed to involve reduced insulin secretion and increased insulin resistance due to HMG-CoA reductase inhibition.
Leveraging data from the Danish health registries, which are renowned for their comprehensive and longitudinal coverage, we aim to examine the temporal dynamics of changes in glycemic levels and diabetes incidence after statin initiation. Specifically, we will capitalize on the wealth of information on statin prescriptions and repeated measurements of glycosylated hemoglobin (HbA1c), an accurate indicator of the average glycemic level.
Deadline: 30 June 2025 23:59 CET